Therefore, concomitant treatment with anti-PD1 antibodies may overcome the immune suppression activity mediated by PD-L1 that is up-regulated by radiotherapy, thus allowing for the generation of more effective anti-tumor immune responses that may lead to long-term tumor control [90]. The gene discussed is CD274; the disease is neoplasm.